Alaw Therapeutics

Alaw Therapeutics is a biotechnology company focused on developing novel therapeutics that target the pyroptosis pathway to treat inflammatory and fibrotic diseases. The company's primary focus is the development of small molecule inhibitors of Gasdermin D, a critical protein that forms pores in cell membranes to release pro-inflammatory cytokines. Founded by leading innate immunity researchers from Yale University and supported by ARCH Venture Partners, Alaw aims to address high unmet needs in conditions such as NASH, sepsis, and various autoimmune disorders. By modulating the body's inflammatory response at the cellular level, the company seeks to prevent tissue damage and disease progression. The platform leverages deep insights into the molecular mechanisms of the inflammasome and cell death to create first-in-class medicines.